Aprea Therapeutics is a clinical-stage precision medicine oncology company developing small molecule inhibitors that exploit synthetic lethality in cancer cells with specific genetic mutations. Its lead programs include APR-1051 (WEE1 inhibitor) in Phase 1 trials, ATRN-119 (ATR inhibitor) with determined RP2D, and APR-1602 (DYRK1A/B inhibitor) in preclinical development. The company targets biomarker-defined cancers, focusing on DNA damage response pathways to selectively kill cancer cells while sparing healthy tissue.
Q2 FY2026 — expected 2026-09-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-16 | 2025-12-31 | 0001104659-26-028068 | EDGAR | 95K words |
| 2025-03-25 | 2024-12-31 | 0001558370-25-003588 | EDGAR | 93K words |
| 2024-03-26 | 2023-12-31 | 0001558370-24-003886 | EDGAR | 96K words |
| 2023-03-30 | 2022-12-31 | 0001558370-23-005126 | EDGAR | 92K words |
| 2022-03-15 | 2021-12-31 | 0001558370-22-003671 | EDGAR | — |
| 2021-03-16 | 2020-12-31 | 0001558370-21-003083 | EDGAR | — |
| 2020-03-27 | 2019-12-31 | 0001558370-20-003257 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-12 | 2026-06-30 | 0001104659-26-094544 | EDGAR | 61K words |
| 2025-11-12 | 2025-09-30 | 0001104659-25-109867 | EDGAR | 61K words |
| 2025-08-12 | 2025-06-30 | 0001558370-25-011152 | EDGAR | 60K words |
| 2025-05-14 | 2025-03-31 | 0001558370-25-007667 | EDGAR | 59K words |
| 2024-11-07 | 2024-09-30 | 0001558370-24-014767 | EDGAR | 61K words |
| 2024-08-12 | 2024-06-30 | 0001558370-24-011806 | EDGAR | 60K words |
| 2024-05-14 | 2024-03-31 | 0001558370-24-008069 | EDGAR | 59K words |
| 2023-11-09 | 2023-09-30 | 0001558370-23-018572 | EDGAR | 62K words |
| 2023-08-10 | 2023-06-30 | 0001558370-23-014405 | EDGAR | 63K words |
| 2023-05-15 | 2023-03-31 | 0001558370-23-009887 | EDGAR | 61K words |
| 2022-11-09 | 2022-09-30 | 0001558370-22-017205 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001558370-22-013512 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-28 | 0001104659-26-102795 | EDGAR | 1K words |
| 2026-08-12 | 0001104659-26-094542 | EDGAR | 3K words |
| 2026-07-23 | 0001104659-26-086254 | EDGAR | 1K words |
| 2026-04-01 | 0001104659-26-038258 | EDGAR | 1K words |
| 2026-03-30 | 0001104659-26-036821 | EDGAR | 4K words |
| 2026-03-16 | 0001104659-26-028046 | EDGAR | 3K words |
| 2026-02-18 | 0001104659-26-016797 | EDGAR | 1K words |
| 2026-01-29 | 0001104659-26-007988 | EDGAR | 4K words |
| 2026-01-23 | 0001104659-26-006267 | EDGAR | 1K words |
| 2026-01-09 | 0001104659-26-002490 | EDGAR | 3K words |
143 total filings indexed. 114 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001781983 |
| Ticker | APRE |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.aprea.com |
| Listed | 2019-10-03 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/APRE (~200 tokens, structured JSON with cryptographic provenance)